338 studies found for:    Open Studies | "Macular Degeneration"
Show Display Options
Rank Status Study
1 Recruiting An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Wet Macular Degeneration;   Macular Degeneration;   Eye Diseases;   Retinal Diseases
Intervention: Device: IRay
2 Recruiting OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
3 Unknown  Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Triamcinolone Acetonide
4 Unknown  Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Microplasmin;   Drug: Placebo control
5 Unknown  Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: ORA102 and Avastin;   Drug: Avastin
6 Recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
7 Recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
8 Unknown  Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Device: Ocular Brachytherapy
9 Recruiting Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
10 Recruiting Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Condition: Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
11 Recruiting Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Condition: Macular Degeneration
Intervention: Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
12 Recruiting Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
13 Unknown  Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Pegaptanib (Macugen®)
14 Recruiting X-82 to Treat Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration (AMD);   Macular Degeneration;   Exudative Age-related Macular Degeneration;   AMD;   Macular Degeneration, Age-related, 10;   Eye Diseases;   Retinal Degeneration;   Retinal Diseases
Interventions: Drug: X-82;   Drug: Aflibercept;   Drug: Placebo
15 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
16 Recruiting A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: DE-122
17 Recruiting To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
18 Recruiting Proton Radiation Therapy for Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
19 Recruiting Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: DS-7080a;   Drug: Ranibizumab
20 Unknown  Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
Condition: Age-Related Neovascular Macular Degeneration
Interventions: Drug: bevacizumab;   Drug: ranibizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years